Browsing by Author "Branes, Jorge"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- ItemPelvic intravenous leiomyomatosis with intracardiac extension. Report of two cases(SOC MEDICA SANTIAGO, 2012) Mertens, Renato; Valdes, Francisco; Munoz, Cecilia; Irarrazaval, Manuel; Branes, Jorge; Riquelme, Carlos; Marine, Leopoldo; Bergoeing, Michel; Kraemer, AlbrechtIntravenous leiomyomatosis with extension into the heart is an infrequent entity described in 1907. Its clinical presentation is non-specific, although cardiac symptoms predominate. Diagnosis is based on clinical findings and appropriate imaging. We report two females, aged 35 and 51 years. One of them presented with a pelvic mass and dyspnea, the other patient had severe cardiac failure on admission. Computed axial tomography scan allowed an accurate preoperative diagnosis on both patients. Successful one stage resection of the tumor was performed under cardiopulmonary bypass. Both patients are asymptomatic on follow up at 6 months and 25 years. (Rev Med Chile 2012; 140: 906-909).
- ItemThe oestrogen metabolite 2-methoxyoestradiol alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand mediates apoptosis in cancerous but not healthy cells of the human endometrium(BIOSCIENTIFICA LTD, 2007) Kato, Sumie; Sadarangani, Anil; Lange, Soledad; Villalon, Manuel; Branes, Jorge; Brosens, Jan J.; Owen, Gareth I.; Cuello, MauricioCancers of the reproductive tract account for 12% of all malignancies in women. As previous studies have shown that oestrogen metabolites can cause apoptosis, we characterised the effect of oestrogen and oestrogen metabolites on non-cancerous and cancerous human endometrial cells. Herein, we demonstrate that 2-methoxyoestradiol (2ME), but not 17 beta-oestradiol, induces apoptosis in cancer cell lines and primary cultured tumours; of endometrial origin. In contrast, 2ME had no effect on cell viability of corresponding normal tissue. This ability of 2ME to induce apoptosis does not require oestrogen receptor activation, but is associated with increased entry into the G2/M phases of the cell cycle and the activation of both the intrinsic and the extrinsic apoptotic pathways. The selective behaviour of 2ME on cancerous as opposed to normal tissue may be due to a reduction in 17 beta -hydroxysteroid dehydrogenase type 11 levels in cancer cells and to a differential down-regulation of superoxide dismutase. Furthermore, we demonstrate that pre-treatment with 2ME enhances the sensitivity of reproductive tract cancer cells to the apoptotic drug tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), without the loss in cell viability to normal cells incurred by currently chemotherapeutic drugs. In conclusion, 2ME, alone or in combination with TRAIL, may be an effective treatment for cancers of uterine origin with minimal toxicity to corresponding healthy female reproductive tissue.